Our previous findings had also revealed that Rb1 exerted anti-angiogenic effects, which may have the therapeutic potential in cardiovascular disease (e.g., atherosclerosis, hypertension, restenosis, etc.), central nervous system diseases (e.g., Alzheimer's disease, stroke, diabetic retinopathy, etc.), chronic inflammatory diseases (e.g., obesity, diabetes, Crohn's disease), and the control cancer development and progression (D'Alessio et al., 2015; Jayakumar et al., 2017; Ramjiawan et al., 2017; Wu et al., 2017). The gene discussed is RB1; the disease is obesity due to melanocortin 4 receptor deficiency.